In vitro evaluation of the interchangeability of different brands of diclofenac sodium tablets available in the Colombian market
Abstract
Introduction: Diclofenac sodium is classified as a non-steroidal anti-inflammatory drug. As diclofenac is an over-the-counter drug, its use among patients cannot be monitored by health teams in follow-up sessions. Given the multiple sources of diclofenac sodium, their interchangeability must be investigated, particularly in the form of in vitro studies, which are the most practical research type and entail minimal ethical commitment.
Objectives: To determine the interchangeability of the different commercial brands of diclofenac sodium relative to the innovative product, this work carries out an in vitro study of eight commercial products of diclofenac sodium (50 mg) following the guidelines of the Biopharmaceutical Classification System.
Materials and methods: Physical and chemical tests were developed following the guidelines of the 39th edition of the United States Pharmacopoeia. An analytical methodology was validated for the quantification of diclofenac according to the current pharmacopoeia and the Q2 guideline ofthe International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Dissolution profiles and their analyseswere governed by the regulations established by the World Health Organization and the national regulations.
Results: All the products passed the physical tests. In the dissolution assays, the acid stage was overcome by all brands, but in the alkaline stage, one brand failed. The analysis of the similarities revealed that only one product was equivalent to the innovator and that three were supra-available, although these brands could also be considered equivalent to the innovator.
Conclusions: Of the eight brands evaluated, three failed the test forthe active principle and the percentage of dissolution. Only one brand was found to be interchangeable with the innovator, and three were identified to besupra-availableand, thus, they do not present a risk for patients.
Downloads
References
Oser B, Melnick D, Hochberg M. Physiological availability of the vitamins. Study of methods for determining availability of vitamins in pharmaceutical products. Ind Eng Chem Anal Ed. 1945;17:405-11. https://doi.org/10.1021/i560143a001
Melnick D, Oser BL. Physiological availability of the vitamins. Vitamins & Hormones. 1947;5:39-92. https://doi.org/10.1016/S0083-6729(08)60806-7
Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12:537-62. https://doi.org/10.1016/0163-7258(81)90097-8
Ministerio de Salud y Protección Social. Resolución 1124, anexo técnico 1. Guía de biodisponibilidad y bioequivalencia - 2016. Fecha de consulta: 21 de julio de 2017. Disponible en: https://www.invima.gov.co/images/bioequivalencia/Resoluci%C3%B3n%201124%20de%202016.pdf
Organización Panamericana de la Salud. Guía para la implementación de estrategias de medicamentos genéricos en los países de América Latina y El Caribe como mecanismo para mejorar el acceso a los medicamentos - 2011. Fecha de consulta: 9 de abril de 2018. Disponible en: http://apps.who.int/medicinedocs/documents/s19196es/
s19196es.pdf
Lawrence XY, Li BV. FDA Bioequivalence Standards. 1a ed. New York: Springer; 2014. p. 465.
Food and Drugs Administration. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products—general considerations. FDA – 2003. Fecha de consulta: 21 de julio de 2017. Disponible en: https://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf
Pérez M, Orobio Y, Baena Y. Estudio comparativo de la liberación in vitro de metformina, a partir de dos productos multifuente de liberación inmediata, comercializados en Colombia. Rev Colomb Cienc Quím Farm. 2013;42:169-89.
Asociación Nacional de Empresarios de Colombia – ANDI. Cifras de la industria farmacéutica -2016. Fecha de consulta: 22 de mayo de 2016. Disponible en: http://www.andi.com.co/pages/proyectos_paginas/proyectos_detail.aspx?pro_id=62&Id=12&clase=8&Tipo=2
Oficina Económica y Comercial de la Embajada de España en Bogotá, Bairexport. El sector de produc-tos farmacéuticos para usohumano en Colombia - 2005. Fecha de consulta: 20 de mayo de 2016. Disponible en: http://www.icex.es/icex/cda/controller page ICEX/0,6558,5518394_5518983_5547593 _577641_0_-1,00.html
Instituto Nacional de Vigilancia de Medicamentos y Alimentos -INVIMA. Normas farmacológicas - 2017. Fecha de consulta: 21 de julio de 2017. Disponible en: https://www.invima.gov.co/images/pdf/tecnovigilancia/documentostecnicos/P-Normas-farmacologicas-2017.pdf
Solano M, Garavito G. Condición de venta de analgésicos antiinflamatorios no esteroides, legalmente autorizados para su comercialización en Colombia. Estrategias de uso racional. Rev Colomb Cienc Quím Farm. 2013;42:145-68.
Chuasuwan B, Binjesoh V, Polli J, Zhang H, Amidon G, Junginger H, et al. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci. 2009;98:1206-19. https://doi.org/10.1002/jps.21525
United States Pharmacopeial Convention. Farmacopea de los Estados Unidos de América : USP 39 : Formulario nacional : NF 34. Formulario Nacional, USP, USP 39 – NF
Rockville, Md. : United States Pharmacopeial Convention; 2016.
International Committee for Harmonization, ICH. Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology - 1996. Fecha de consulta: 21 de julio de 2017. Disponible en: http://www.ich.org/products/guidelines/quality/quality-single/article/validation-ofanalytical-procedures-text-and-methodology.html
O’Hara T, Dunne A, Butler J, Devane J. A review of methods used to compare dissolution profile data. Pharm Sci Technol Today. 1998;1:214-23. https://doi.org/10.1016/S1461-5347(98)00053-4
Shah VP, Tsong Y, Sathe P, Liu J-P. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15:889-96. https://doi.org/10.1023/A:1011976615750
Matiz GE, Rodríguez E. Estudio comparativo de la calidad biofarmacéutica de marcas comerciales y multifuentes de tabletas de captopril y losartán del mercado colombiano. Rev Colomb Ciencias Quim Farm. 2014;43:217-33. https://doi.org/10.15446/rcciquifa
Franco LA, Matiz GE, Pájaro I. Estudio biofarmacéutico comparativo de marcas comerciales de tabletas de ciprofloxacino disponibles en el mercado colombiano. Rev Salud Pública (Bogotá). 2012;14:695-709.
Khan K. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48-9. https://doi.org/10.1111/j.2042-7158.1975.tb09378.x
Serra C, Storpirtis S. Comparação de perfis de dissolução da cefalexina através de estudos de cinética e eficiência de dissolução (ED por cento). Rev Bras Ciênc Farm. 2007;43:79-88. https://doi.org/10.1590/S1516-93322007000100010
Villaroel A, Clement Y, Sealy P, Löbenberg R, Montane L, Maharaj R, et al. Comparing the dissolution profiles of seven metformin formulations in simulated intestinal fluid. Dissolution Technologies. 2015;22:17-22. https://doi.org/10.14227/DT220115P17
Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int J Pharm. 1993;97:93-100. https://doi.org/10.1016/0378-5173(93)90129-4
Azarmi S, Roa W, Löbenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm. 2007;328:12-21. https://doi.org/10.1016/j.ijpharm.2006.10.001
Food and Drugs Administration. Waiver of in vivo bioavailability and bioequivalence studies for imme- diaterelease solid oral dosage forms based on a biopharmaceutics classification system: Guidance for industry. Fecha de consulta: 21 de julio de 2017. Disponible en: https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf
Frutos G, Ocaña J. Técnicas de remuestreo en la comparación de curvas de disolución de fármacos. An Real Acad Farm. 2011;77:1-19.
Stevens R, Gray V, Dorantes A, Gold L, Pham L. Scientific and regulatory standards for assessing product performance using the similarity factor, f2. AAPS J. 2015;17:301-6. https://doi.org/10.1208/s12248-015-9723-y 27.
Wadher KJ, Kakde RB, Umekar MJ. Development of a sustained-release tablet of metformin hydrochloride containing hydrophilic eudragit and ethyl cellulose polymer. International Journal of Comprehensive Pharmacy. 2011;2:1-6.
Ministerio de Salud y Protección Social. Lineamientos para la implementación de la política de seguridad del paciente en la República de Colombia - 2008. Fecha de consulta: 21 de julio de 2017. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/LINEAMIENTOS_IMPLEMENTACION_POLITICA_
SEGURIDAD_DEL_PACIENTE.pdf
Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, et al. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59:80-4. https://doi.org/10.1111/j.1365-2125.2005.02226.x
World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. WHO Technical Report Series, No. 992, Annex 7. Fecha de consulta: 9 de abril de 2018. Disponible en: http://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex7-TRS992.pdf
Some similar items:
- Eliana P. Calvo, María O. Rojas, Jacqueline Chaparro, Moisés Wasserman, Expresion of the multiple drug resistance associated gene (pfMDR 1) in Colombian strains of Plasmodium falciparum , Biomedica: Vol. 19 No. 3 (1999)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
